References

  1. 1.Practice Committee of the American Society for Reproductive Medicine. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril. 2020;113(3):533-535.
  2. 2.American Urological Association, American Society for Reproductive Medicine. Diagnosis and treatment of infertility in men: AUA/ASRM guideline. https://www.auanet.org/guidelines-and-quality/guidelines/male-infertility
  3. 3.Tielemans E, Burdorf A, te Velde E, et al. Sources of bias in studies among infertility clients. Am J Epidemiol. 2002;156(1):86-92.
  4. 4.Thonneau P, Marchand S, Tallec A, et al. Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988-1989). Hum Reprod. 1991;6(6):811-816.
  5. 5.Leridon H. Can assisted reproduction technology compensate for the natural decline in fertility with age? A model assessment. Hum Reprod. 2004;19(7):1548-1553.
  6. 6.American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee. Female age-related fertility decline. Committee Opinion No. 589. Fertil Steril. 2014;101(3):633-634.
  7. 7.Niederberger CS. Male infertility. In: Wein AJ , KavoussiL R, Partin AW, et al., eds. Campbell-Walsh Urology. 12th ed. 2016; Elsevier:1781-1844.
  8. 8.Ghomeshi A, Yang B, Masterson TA. The adverse effects of commonly used medications on male fertility: a comprehensive review. F S Rev. 2023;4(3):176-186.
  9. 9.WHO Laboratory Manual For the Examination and Processing of Human Semen. 5th ed. World Health Organization; 2010.
  10. 10.Carson SA, Kallen AN. Diagnosis and management of infertility: a review. JAMA. 2021;326(1):65-76.
  11. 11.Practice Committee of the American Society for Reproductive Medicine. Tobacco or marijuana use and infertility: a committee opinion. Fertil Steril. 2024;121(4):589-603.
  12. 12.Jensterle M, Janez A, Fliers E, et al. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum Reprod Update. 2019;25(4):504-517.
  13. 13.Garvey WT, Mechanick JI, Brett EM, et al.; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(3 suppl):1-203.
  14. 14.Duran HE, Morshedi M, Kruger T, et al. Intrauterine insemination: a systematic review on determinants of success. Hum Reprod Update. 2002;8(4):373-384.
  15. 15.Cissen M, Bensdorp A, Cohlen BJ, et al. Assisted reproductive technologies for male subfertility. Cochrane Database Syst Rev. 2016(2):CD000360.
  16. 16.Farquhar C, Marjoribanks J. Assisted reproductive technology: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2018(8):CD010537.
  17. 17.Iwamoto A, Van Voorhis BJ, Summers KM, et al. Intracytoplasmic sperm injection vs. conventional in vitro fertilization in patients with non-male factor infertility. Fertil Steril. 2022;118(3):465-472.
  18. 18.Sexual dysfunctions. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed., text revision. American Psychiatric Association; 2022:477-510.
  19. 19.Meissner VH, Schroeter L, Köhn FM, et al. Factors associated with low sexual desire in 45-year-old men: findings from the German Male Sex-Study. J Sex Med. 2019;16(7):981-991.
  20. 20.Ertl N, Mills EG, Wall MB, et al. Women and men with distressing low sexual desire exhibit sexually dimorphic brain processing. Sci Rep. 2024;14(1):11051.
  21. 21.Laumann EO, Nicolosi A, Glasser DB, et al.; GSSAB Investigators’ Group. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res. 2005;17(1):39-57.
  22. 22.European Association of Urology. 7. Low sexual desire and male hypoactive sexual desire disorder. Sexual and reproductive health. https://uroweb.org/guidelines/sexual-and-reproductive-health/chapter/low-sexual-desire-and-male-hypoactive-sexual-desire-disorder
  23. 23.Spector IP, Carey MP, Steinberg L. The sexual desire inventory: development, factor structure, and evidence of reliability. J Sex Marital Ther. 1996;22(3):175-190.
  24. 24.Moyano N, Vallejo-Medina P, Sierra JC. Sexual Desire Inventory: two or three dimensions? J Sex Res. 2017;54(1):105-116.
  25. 25.Rubio-Aurioles E, Bivalacqua TJ. Standard operational procedures for low sexual desire in men. J Sex Med. 2013;10(1):94-107.
  26. 26.American Urological Association. Evaluation and management of testosterone deficiency (2024). https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline
  27. 27.Melmed S, Casanueva FF, Hoffman AR, et al. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288.
  28. 28.Kravets I. Hyperthyroidism: diagnosis and treatment. Am Fam Physician. 2016;93(5):363-370.
  29. 29.Wilson SA, Stem LA, Bruehlman RD. Hypothyroidism: diagnosis and treatment. Am Fam Physician. 2021;103(10):605-613.
  30. 30.Pippitt K, Li M, Gurgle HE. Diabetes mellitus: screening and diagnosis. Am Fam Physician. 2016;93(2):103-109.
  31. 31.Parish SJ, Hahn SR. Hypoactive sexual desire disorder: a review of epidemiology, biopsychology, diagnosis, and treatment. Sex Med Rev. 2016;4(2):103-120.
  32. 32.Gehring D. Couple therapy for low sexual desire: a systemic approach. J Sex Marital Ther. 2003;29(1):25-38.
  33. 33.Heidelbaugh JJ, Belakovskiy A. Testosterone replacement therapy for male hypogonadism. Am Fam Physician. 2024;109(6):543-549.
  1. 1.Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633-641.
  2. 2.Sexual dysfunctions. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed., text revision. American Psychiatric Association; 2022:477-510.
  3. 3.Yafi FA, Jenkins L, Albersen M, et al. Erectile dysfunction. Nat Rev Dis Primers. 2016;2:16003.
  4. 4.Allen MS, Wood AM, Sheffield D. The psychology of erectile dysfunction. Curr Dir Psychol Sci. 2023;32(6):487-493.
  5. 5.Geerkens MJM, Al-Itejawi HHM, Nieuwenhuijzen JA, et al. Sexual dysfunction and bother due to erectile dysfunction in the healthy elderly male population: prevalence from a systematic review. Eur Urol Focus. 2020;6(4):776-790.
  6. 6.Bravi CA, Tin A, Montorsi F, et al. Erectile function and sexual satisfaction: the importance of asking about sexual desire. J Sex Med. 2020;17(2):349-352.
  7. 7.Mostyn P, Morgan L. Are men with erectile dysfunction able to ejaculate?—a survey. J Forensic Leg Med. 2013;20(4):239-241.
  8. 8.National Library of Medicine. Erection problems. MedlinePlus. https://medlineplus.gov/ency/article/007617.htm
  9. 9.Sheng Z. Psychological consequences of erectile dysfunction. Trends Urol Men’s Health. 2021;12(6):19-22.
  10. 10.Maestre-Lorén F, Castillo-Garayoa JA, López-I-Martín X, et al. Psychological distress in erectile dysfunction: the moderating role of attachment. Sex Med. 2021;9(5):100436.
  11. 11.Irwin GM. Erectile dysfunction. Prim Care. 2019;46(2):249-255.
  12. 12.Rew KT, Heidelbaugh JJ. Erectile dysfunction. Am Fam Physician. 2016;94(10):820-827.
  13. 13.Diaz VA, Close JD. Male sexual dysfunction. Prim Care. 2010;37(3):473-489.
  14. 14.Corona G. Erectile dysfunction and premature ejaculation: a continuum movens supporting couple sexual dysfunction. J Endocrinol Invest. 2022;45(11):2029-2041.
  15. 15.Mulhall JP, Goldstein I, Bushmakin AG, et al. Validation of the erection hardness score. J Sex Med. 2007;4(6):1626-1634.
  16. 16.Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49(6):822-830.
  17. 17.Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11(6):319-326.
  18. 18.van Kollenburg RAA, de Bruin DM, Wijkstra H. Validation of the electronic version of the International Index of Erectile Function (IIEF-5 and IIEF-15): a crossover study. J Med Internet Res. 2019;21(7):e13490.
  19. 19.Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432.
  20. 20.Al-Zubaidi M, Hawks C, Fernando S, et al. Relationship between lower urinary tract symptoms (LUTS) and prostate cancer: a persistent myth. J Clin Urol. 2023.
  21. 21.Petering RC, Brooks NA. Testosterone therapy: review of clinical applications. Am Fam Physician. 2017;96(7):441-449.
  22. 22.Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. P&T. 2013;38(7):407-419.
  23. 23.Lee M. Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men. Clin Ther. 2011;33(11):1590-1608.
  24. 24.Rajagopalan P, Mazzu A, Xia C, et al. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol. 2003;43(3):260-267.
  25. 25.Seftel AD. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin Cardiol. 2004;27(4):I14-I19.
  26. 26.Zinner N. Do food and dose timing affect the efficacy of sildenafil? A randomized placebo-controlled study. J Sex Med. 2007;4(1):137-144.
  27. 27.Bivalacqua TJ, Allen BK, Brock G, et al. Acute ischemic priapism: an AUA/SMSNA guideline. J Urol. 2021;206(5):1114-1121.
  28. 28.Bivalacqua TJ, Allen BK, Brock GB, et al. The diagnosis and management of recurrent ischemic priapism, priapism in sickle cell patients, and non-ischemic priapism: an AUA/SMSNA guideline. J Urol. 2022;208(1):43-52.
  29. 29.Muneer A. Comparison of EAU and UK guidelines on priapism. J Clin Urol. 2018;11(2):127-131.
  30. 30.Shigehara K, Namiki M. Clinical management of priapism: a review. World J Mens Health. 2016;34(1):1-8.
  31. 31.Roghmann F, Becker A, Sammon JD, et al. Incidence of priapism in emergency departments in the United States. J Urol. 2013;190(4):1275-1280.
  32. 32.Hosny K, Nosseir M, Pearce I. Malignant priapism: review of the report in three decades. J Clin Urol. 2020;13(5):382-391.
  33. 33.Hudnall M, Reed-Maldonado AB, Lue TF. Advances in the understanding of priapism. Transl Androl Urol. 2017;6(2):199-206.
  34. 34.Asanad K, Halpern JA, Brannigan RE. What is priapism? JAMA. 2024;331(15):1340.
  35. 35.Ortaç M, Çevik G, Akdere H, et al. Anatomic and functional outcome following distal shunt and tunneling for treatment ischemic priapism: a single-center experience. J Sex Med. 2019;16(8):1290-1296.
  36. 36.Addar A, Al Fraidi O, Nazer A, et al. Priapism for 10 days in a patient with SARS-CoV-2 pneumonia: a case report. J Surg Case Rep. 2021;2021(4):rjab020.
  37. 37.Alnajjar HM, Muneer A. Recent advances in understanding and treating priapism. Fac Rev. 2022;11:23.
  38. 38.Bintoro SUY, Romadhon PZ, Suryantoro SD, et al. Case report: priapism as the clinical presenting feature of chronic myeloid leukemia: case report and 20-year literature review. F1000 Res. 2021;10:571.
  39. 39.Boucher-Hayes D, Nolan P, Pate G. Treatment-resistant priapism associated with long-term low-molecular-weight heparin. BMJ Case Rep. 2021;14(4):e241897.
  40. 40.Ericson C, Baird B, Broderick GA. Management of priapism: 2021 update. Urol Clin North Am. 2021;48(4):565-576.
  41. 41.James Johnson M, Hallerstrom M, Alnajjar HM, et al. Which patients with ischemic priapism require further investigation for malignancy? Int J Impot Res. 2020;32(2):195-200.
  42. 42.Karayagmurlu A, Coskun M. Successful management of methylphenidate or atomoxetine-related priapism during attention-deficit hyperactivity disorder treatment. J Clin Psychopharmacol. 2020;40(3):314-315.
  43. 43.Olson C, Jhawar A, Elfessi Z, et al. Hydroxyzine-induced priapism. Am J Emerg Med. 2021;48:375.e5-375.e6.
  44. 44.Tabei SS, Baas W, Brooks A, et al. Malignant priapism: case report and update on management protocols. Transl Androl Urol. 2023;12(10):1607-1613.
  45. 45.De Niro AJN, Duarsa GWK, Yudiana IW, et al. Predictors of priapism incidence and recurrence in sickle cell disease patients. Afr J Urol. 2023;29:45.
  46. 46.Rezaee ME, Gross MS. Are we overstating the risk of priapism with oral phosphodiesterase type 5 inhibitors? J Sex Med. 2020;17(8):1579-1582.
  47. 47.Alvey L, Tabei SS, Baas W. Treatment of obstructive sleep apnea relieves stuttering priapism in patient with sickle cell disease: a case report. Transl Androl Urol. 2024;13(7):1297-1301.
  48. 48.Joice GA, Liu JL, Burnett AL. Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm. BJU Int. 2021;127(5):498-506.
  49. 49.Manjunatha N, Benegal V. Stuttering priapism associated with topiramate. Gen Hosp Psychiatry. 2015;37(6):620.e1-620.e2.
  50. 50.Offenbacher J, Barbera A. Penile emergencies. Emerg Med Clin North Am. 2019;37(4):583-592.
  51. 51.Kousournas G, Muneer A, Ralph D, et al. Contemporary best practice in the evaluation and management of stuttering priapism. Ther Adv Urol. 2017;9(9-10):227-238.
  52. 52.Palka J, DuComb W, Begun E, et al. Factors associated with corporoglandular shunting for patients with first-time ischemic priapism. Urology. 2021;154:191-195.
  53. 53.Drake T, Rustom J, Davies M. Phimosis in childhood. BMJ. 2013;346:f3678.
  54. 54.Morris BJ, Matthews JG, Krieger JN. Prevalence of phimosis in males of all ages: systematic review. Urology. 2020;135:124-132.
  55. 55.Denniston GC, Hill G. Gairdner was wrong. Can Fam Physician. 2010;56(10):986-987.
  56. 56.McGregor TB, Pike JG, Leonard MP. Pathologic and physiologic phimosis: approach to the phimotic foreskin. Can Fam Physician. 2007;53(3):445-448.
  57. 57.Radmayr C, Bogaert G, Bujons A, et al.; EAU Guidelines on Paediatric Urology. https://uroweb.org/guidelines/paediatric-urology
  58. 58.Moreno G, Ramirez C, Corbalán J, et al. Topical corticosteroids for treating phimosis in boys. Cochrane Database Syst Rev. 2024(1):CD008973.
  59. 59.Nguyen ATM, Holland AJA. Balanitis xerotica obliterans: an update for clinicians. Eur J Pediatr. 2020;179(1):9-16.
  60. 60.Charlton OA, Smith SD. Balanitis xerotica obliterans: a review of diagnosis and management. Int J Dermatol. 2019;58(7):777-781.
  61. 61.Celis S, Reed F, Murphy F, et al. Balanitis xerotica obliterans in children and adolescents: a literature review and clinical series. J Pediatr Urol. 2014;10(1):34-39.
  62. 62.Bromage SJ, Crump A, Pearce I. Phimosis as a presenting feature of diabetes. BJU Int. 2008;101(3):338-340.
  63. 63.Sneppen I, Thorup J. Foreskin morbidity in uncircumcised males. Pediatrics. 2016;137(5):e20154340.
  64. 64.Czajkowski M, Czajkowska K, Zarańska K, et al. Male circumcision due to phimosis as the procedure that is not only relieving clinical symptoms of phimosis but also improves the quality of sexual life. Sex Med. 2021;9(2):100315.
  65. 65.Herzog LW, Alvarez SR. The frequency of foreskin problems in uncircumcised children. Am J Dis Child. 1986;140(3):254-256.
  66. 66.Porche DJ. Paraphimosis: an emergency condition. J Nurse Pract. 2006;2(8):606-607.
  67. 67.Palmisano F, Gadda F, Spinelli MG, et al. Glans penis necrosis following paraphimosis: a rare case with brief literature review. Urol Case Rep. 2017;16:57-58.
  68. 68.Abbas T, McCarthy L. Foreskin and penile problems in childhood. Surgery (Oxf). 2022;40(5):326-331.
  69. 69.Burstein B, Paquin R. Comparison of outcomes for pediatric paraphimosis reduction using topical anesthetic versus intravenous procedural sedation. Am J Emerg Med. 2017;35(10):1391-1395.
  70. 70.Vunda A, Lacroix LE, Schneider F, et al. Videos in clinical medicine. Reduction of paraphimosis in boys. N Engl J Med. 2013;368(13):e16.
  71. 71.Clifford ID, Craig SS, Nataraja RM, et al. Paediatric paraphimosis. Emerg Med Australas. 2016;28(1):96-99.
  72. 72.Pohlman GD, Phillips JM, Wilcox DT. Simple method of paraphimosis reduction revisited: point of technique and review of the literature. J Pediatr Urol. 2013;9(1):104-107.
  73. 73.Manjunath AS, Hofer MD. Urologic emergencies. Med Clin North Am. 2018;102(2):373-385.
  74. 74.Nehra A, Alterowitz R, Culkin DJ, et al.; American Urological Association Education and Research, Inc. Peyronie’s disease: AUA guideline. J Urol. 2015;194(3):745-753.
  75. 75.Patel DP, Christensen MB, Hotaling JM, et al. A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie’s disease. World J Urol. 2020;38(2):253-261.
  76. 76.Segundo A, Glina S. Prevalence, risk factors, and erectile dysfunction associated with Peyronie’s disease among men seeking urological care. Sex Med. 2020;8(2):230-236.
  77. 77.Al-Thakafi S, Al-Hathal N. Peyronie’s disease: a literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up. Transl Androl Urol. 2016;5(3):280-289.
  78. 78.Brimley SC, Yafi FA, Greenberg J, et al. Review of management options for active-phase Peyronie’s disease. Sex Med Rev. 2019;7(2):329-337.
  79. 79.Pastuszak AW, Rodriguez KM, Solomon ZJ, et al. Increased risk of incident disease in men with Peyronie’s disease: analysis of U.S. claims data. J Sex Med. 2018;15(6):894-901.
  80. 80.Nugteren HM, Nijman JM, de Jong IJ, et al. The association between Peyronie’s and Dupuytren’s disease. Int J Impot Res. 2011;23(4):142-145.
  81. 81.de Jesús MR, Ramasamy R, Ibrahim E, et al. The use of ultrasonography in the evaluation and management of Peyronie’s disease. Urol Video J. 2020;7:100047.
  82. 82.Kozub A, Suleja A, Chłosta M, et al. Current trends in non-surgical management of Peyronie’s disease–a narrative review. Andrology. 2024;12(3):505-517.
  1. 1.Althof SE, McMahon CG, Waldinger MD, et al. An update of the International Society of Sexual Medicine’s guidelines for the diagnosis and treatment of premature ejaculation (PE). Sex Med. 2014;2(2):60-90.
  2. 2.Shindel AW, Althof SE, Carrier S, et al. Disorders of ejaculation: an AUA/SMSNA guideline. J Urol. 2022;207(3):504-512.
  3. 3.Sexual Dysfunctions. Diagnostic and Statistical Manual of Mental Disorders. 5th ed., text revision. American Psychiatric Association; 2022:477-510.
  4. 4.Rowland DL, Kolba TN. Understanding the effects of establishing various cutoff criteria in the definition of men with premature ejaculation. J Sex Med. 2015;12(5):1175-1183.
  5. 5.Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537-544.
  6. 6.Donatucci CF. Etiology of ejaculation and pathophysiology of premature ejaculation. J Sex Med. 2006;3(4 suppl):303-308.
  7. 7.Guo L, Liu Y, Wang X, et al. Significance of penile hypersensitivity in premature ejaculation. Sci Rep. 2017;7(1):10441.
  8. 8.Serefoglu EC, McMahon CG, Waldinger MD, et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. J Sex Med. 2014;11(6):1423-1441.
  9. 9.Gul M, Bocu K, Serefoglu EC. Current and emerging treatment options for premature ejaculation. Nat Rev Urol. 2022;19(11):659-680.
  10. 10.Haensel SM, Rowland DL, Kallan KT. Clomipramine and sexual function in men with premature ejaculation and controls. J Urol. 1996;156(4):1310-1315.
  11. 11.Waldinger MD, Zwinderman AH, Schweitzer DH, et al. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res. 2004;16(4):369-381.
  12. 12.Kim SW, Choi JB, Kim SJ, et al. Tolerability and adequate therapeutic dosage of oral clomipramine for the treatment of premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose, parallel-grouped clinical study. Int J Impot Res. 2018;30(2):65-70.
  13. 13.Choi JB, Kang SH, Lee DH, et al. Efficacy and safety of on demand clomipramine for the treatment of premature ejaculation: a multicenter, randomized, double-blind, phase III clinical trial. J Urol. 2019;201(1):147-152.
  14. 14.Martyn-St James M, Cooper K, Ren S, et al. Phosphodiesterase type 5 inhibitors for premature ejaculation: a systematic review and meta-analysis. Eur Urol Focus. 2017;3(1):119-129.
  15. 15.Wu T, Yue X, Duan X, et al. Efficacy and safety of tramadol for premature ejaculation: a systematic review and meta-analysis. Urology. 2012;80(3):618-624.
  16. 16.Dinsmore WW, Wyllie MG. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study. BJU Int. 2009;103(7):940-949.
  17. 17.Cooper K, Martyn-St James M, Kaltenthaler E, et al. Behavioral therapies for management of premature ejaculation: a systematic review. Sex Med. 2015;3(3):174-188.
  18. 18.Semans JH. Premature ejaculation: a new approach. South Med J. 1956;49(4):353-358.
  19. 19.Melnik T, Althof S, Atallah AN, et al. Psychosocial interventions for premature ejaculation. Cochrane Database Syst Rev. 2011(8):CD008195.
  20. 20.Di Sante S, Mollaioli D, Gravina GL, et al. Epidemiology of delayed ejaculation. Transl Androl Urol. 2016;5(4):541-548.
  21. 21.Waldinger MD, Quinn P, Dilleen M, et al. A multinational population survey of intravaginal ejaculation latency time. J Sex Med. 2005;2(4):492-497.
  22. 22.Paduch DA, Polzer P, Morgentaler A, et al. Clinical and demographic correlates of ejaculatory dysfunctions other than premature ejaculation: a prospective, observational study. J Sex Med. 2015;12(12):2276-2286.
  23. 23.Abdel-Hamid IA, Ali OI. Delayed ejaculation: pathophysiology, diagnosis, and treatment. World J Mens Health. 2018;36(1):22-40.
  24. 24.Fiala L, Lenz J, Havelka P, et al. Delayed ejaculation in men with depressive disorders. Andrologia. 2022;54(6):e14412.
  25. 25.Abdel-Hamid IA, Elsaied MA, Mostafa T. The drug treatment of delayed ejaculation. Transl Androl Urol. 2016;5(4):576-591.
  26. 26.Paduch DA, Polzer PK, Ni X, et al. Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. J Clin Endocrinol Metab. 2015;100(8):2956-2962.
  27. 27.Abdel-Hamid IA, Saleh S. Primary lifelong delayed ejaculation: characteristics and response to bupropion. J Sex Med. 2011;8(6):1772-1779.
  28. 28.Hisasue S, Furuya R, Itoh N, et al. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol. 2006;13(10):1311-1316.
  29. 29.Althof SE. Psychological interventions for delayed ejaculation/orgasm. Int J Impot Res. 2012;24(4):131-136.
  30. 30.Parnham A, Serefoglu EC. Retrograde ejaculation, painful ejaculation and hematospermia. Transl Androl Urol. 2016;5(4):592-601.
  31. 31.Jefferys A, Siassakos D, Wardle P. The management of retrograde ejaculation: a systematic review and update. Fertil Steril. 2012;97(2):306-312.
  32. 32.Roughley M, Lyall M. Retrograde ejaculation associated with quetiapine and treatment with low-dose imipramine. BMJ Case Rep. 2019;12(8):e228539.
  33. 33.Cooper TG, Noonan E, von Eckardstein S, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update. 2010;16(3):231-245.
  34. 34.McMahon CG. 71. Disorders of male orgasm and ejaculation. In: Partin AW, Dmochowski RR, Kavoussi LR, et al., eds. Campbell-Walsh-Wein Urology. 12th ed. Elsevier; 2021: 1564-1581.
  35. 35.Shoshany O, Abhyankar N, Elyaguov J, et al. Efficacy of treatment with pseudoephedrine in men with retrograde ejaculation. Andrology. 2017;5(4):744-748.
  36. 36.Ochsenkühn R, Kamischke A, Nieschlag E. Imipramine for successful treatment of retrograde ejaculation caused by retroperitoneal surgery. Int J Androl. 1999;22(3):173-177.
  37. 37.Mehta A, Sigman M. Management of the dry ejaculate: a systematic review of aspermia and retrograde ejaculation. Fertil Steril. 2015;104(5):1074-1081.
  38. 38.Ilie CP, Mischianu DL, Pemberton RJ. Painful ejaculation. BJU Int. 2007;99(6):1335-1339.
  39. 39.Cohen D, Gonzalez J, Goldstein I. The role of pelvic floor muscles in male sexual dysfunction and pelvic pain. Sex Med Rev. 2016;4(1):53-62.
  40. 40.Mathers MJ, Degener S, Sperling H, et al. Hematospermia–a symptom with many possible causes. Dtsch Arztebl Int. 2017;114(11):186-191.
  41. 41.Polito M, Giannubilo W, d’Anzeo G, et al. Hematospermia: diagnosis and treatment. Arch Ital Urol Androl. 2006;78(2):82-85.
  42. 42.Suh Y, Gandhi J, Joshi G, et al. Etiologic classification, evaluation, and management of hematospermia. Transl Androl Urol. 2017;6(5):959-972.
  43. 43.Stefanovic KB, Gregg PC, Soung M. Evaluation and treatment of hematospermia. Am Fam Physician. 2009;80(12):1421-1427.
  44. 44.Madhushankha M, Jayarajah U, Abeygunasekera AM. Clinical characteristics, etiology, management and outcome of hematospermia: a systematic review. Am J Clin Exp Urol. 2021;9(1):1-17.
  1. 1.Centers for Disease Control and Prevention. National overview of STIs in 2023. https://www.cdc.gov/sti-statistics/annual/summary.html
  2. 2.Centers for Disease Control. Discussing sexual health with your patients. https://www.cdc.gov/hivnexus/hcp/sexual-history/index.html
  3. 3.National Coalition For Sexual Health. A new approach to sexual history taking: a video series. https://nationalcoalitionforsexualhealth.org/tools/for-healthcare-providers/video-series
  4. 4.Centers for Disease Control and Prevention. How to prevent STIs. https://www.cdc.gov/sti/prevention/index.html
  5. 5.Centers for Disease Control and Prevention. Getting tested for STIs. Sexually transmitted infections (STIs). https://www.cdc.gov/sti/testing/index.html
  6. 6.US Preventive Services Task Force. Final recommendation statement. Chlamydia and gonorrhea: screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/chlamydia-and-gonorrhea-screening
  7. 7.US Preventive Services Task Force. Final recommendation statement. Human immunodeficiency virus (HIV) infection: screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/human-immunodeficiency-virus-hiv-infection-screening
  8. 8.Centers for Disease Control and Prevention. Screening recommendations and considerations referenced in treatment guidelines and original sources. https://www.cdc.gov/std/treatment-guidelines/screening-recommendations.htm
  9. 9.Owens DK, Davidson KW, Krist AH, et al.; US Preventive Services Task Force. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2020;323(10):970-975.
  10. 10.Centers for Disease Control and Prevention, National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention. STI prevention priorities. https://www.cdc.gov/nchhstp/priorities/std-prevention.html
  11. 11.Bachmann LH, Barbee LA, Chan P, et al. CDC clinical guidelines on the use of doxycycline postexposure prophylaxis for bacterial sexually transmitted infection prevention, United States, 2024. MMWR Recomm Rep. 2024;73(2):1-8.
  12. 12.Centers for Disease Control. Expedited partner therapy. https://www.cdc.gov/std/ept/default.htm
  13. 13.Barbee LA, St Cyr SB. Management of Neisseria gonorrhoeae in the United States: summary of evidence from the development of the 2020 gonorrhea treatment recommendations and the 2021 Centers for Disease Control and Prevention sexually transmitted infection treatment guidelines. Clin Infect Dis. 2022;74(2 suppl):S95-S111.
  14. 14.Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187.
  15. 15.Silverberg B, Moyers A, Hinkle T, et al. 2021 CDC update: treatment and complications of sexually transmitted infections (STIs). Venereology (Basel). 2022;1(1):23-46.
  16. 16.Centers for Disease Control and Prevention. Gonococcal infections among adolescents and adults. https://www.cdc.gov/std/treatment-guidelines/gonorrhea-adults.htm
  17. 17.World Health Organization (WHO). Global health sector strategy on sexually transmitted infections, 2016-2021. WHO; 2016. https://www.who.int/publications/i/item/WHO-RHR-16.09
  18. 18.Ibáñez-Escribano A, Nogal-Ruiz JJ. The past, present, and future in the diagnosis of a neglected sexually transmitted infection: trichomoniasis. Pathogens. 2024;13(2):126.
  19. 19.González-Beiras C, Marks M, Chen CY, et al. Epidemiology of Haemophilus ducreyi infections. Emerg Infect Dis. 2016;22(1):1-8.
  20. 20.Heslop R, Roberts H, Flower D, et al. Interventions for men and women with their first episode of genital herpes. Cochrane Database Syst Rev. 2016;2016(8):CD010684.
  21. 21.Marciano S, Arufe D, Haddad L, et al. Outbreak of hepatitis A in a post-vaccination era: high rate of co-infection with sexually transmitted diseases. Ann Hepatol. 2020;19(6):641-644.
  22. 22.Krist AH, Davidson KW, Mangione CM, et al.; US Preventive Services Task Force. Screening for hepatitis B virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. JAMA. 2020;324(23):2415-2422.
  23. 23.Deeks SG, Overbaugh J, Phillips A, et al. HIV infection. Nat Rev Dis Primers. 2015;1(1):15035.
  24. 24.Bosh KA, Hall HI, Eastham L, et al. Estimated annual number of HIV infections — United States, 1981-2019. MMWR Morb Mortal Wkly Rep. 2021;70(22):801-806.
  25. 25.Prince MA, Tan MC, Tan MX, et al. Exploring the impact of therapeutic advances in HIV-related mortality in the United States. IJID Reg. 2024;11:100347.
  26. 26.Petagna CN, Perez S, Hsu E, et al. Facilitators and barriers of HPV vaccination: a qualitative study in rural Georgia. BMC Cancer. 2024;24(1):592.
  27. 27.Castaneda D, Gonzalez AJ, Alomari M, et al. From hepatitis A to E: a critical review of viral hepatitis. World J Gastroenterol. 2021;27(16):1691-1715.
  28. 28.McKay L, Clery H, Carrick-Anderson K, et al. Genital Chlamydia trachomatis infection in a subgroup of young men in the UK. Lancet. 2003;361(9371):1792.
  29. 29.Baumann L, Cina M, Egli-Gany D, et al. Prevalence of Mycoplasma genitalium in different population groups: systematic review and meta-analysis. Sex Transm Infect. 2018;94(4):255-262.
  30. 30.Obafemi OA, Rowan SE, Nishiyama M, et al. Mycoplasma genitalium: key information for the primary care clinician. Med Clin North Am. 2024;108(2):297-310.
  31. 31.Cox C, McKenna JP, Watt AP, et al. Ureaplasma parvum and Mycoplasma genitalium are found to be significantly associated with microscopy-confirmed urethritis in a routine genitourinary medicine setting. Int J STD AIDS. 2016;27(10):861-867.
  32. 32.Beeton ML, Payne MS, Jones L. The role of Ureaplasma spp. in the development of nongonococcal urethritis and infertility among men. Clin Microbiol Rev. 2019;32(4):e00137-e18.
  33. 33.Coker TJ, Dierfeldt DM. Acute bacterial prostatitis: diagnosis and management. Am Fam Physician. 2016;93(2):114-120.
  34. 34.Centers for Disease Control and Prevention. Mycoplasma genitalium. https://www.cdc.gov/std/treatment-guidelines/mycoplasmagenitalium.htm
  35. 35.Zhang QF, Zhang YJ, Wang S, et al. The effect of screening and treatment of Ureaplasma urealyticum infection on semen parameters in asymptomatic leukocytospermia: a case-control study. BMC Urol. 2020;20(1):165.
  36. 36.Seña AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis. 2007;44(1):13-22.
  37. 37.Papp JR, Park IU, Fakile Y, et al. CDC laboratory recommendations for syphilis testing, United States, 2024. MMWR Recomm Rep. 2024;73(1):1-32.
  38. 38.World Health Organization. Data on syphilis. The Global Health Observatory. https://www.who.int/data/gho/data/themes/topics/data-on-syphilis
  39. 39.Lewis DA. Epidemiology, clinical features, diagnosis and treatment of Haemophilus ducreyi – a disappearing pathogen? Expert Rev Anti Infect Ther. 2014;12(6):687-696.
  40. 40.Centers for Disease Control and Prevention. Table 1. Sexually transmitted infections – reported cases and rates of reported cases*, United States 1941-2023. https://www.cdc.gov/sti-statistics/data-vis/table-sticasesrates.html
  41. 41.World Health Organization. Clinical management and infection prevention and control for monkeypox: interim rapid response guidance, 10 June 2022. https://www.who.int/publications/i/item/WHO-MPX-Clinical-and-IPC-2022.1
  42. 42.Yeshiwas AG, Temesegen A, Melkie G, et al. Assessing healthcare workers’ confidence level in diagnosing and managing emerging infectious virus of human mpox in hospitals in Amhara Region, Northwest Ethiopia: multicentre institution-based cross-sectional study. BMJ Open. 2024;14(7):e080791.
  43. 43.Centers for Disease Control and Prevention. About mpox. https://www.cdc.gov/mpox/about/index.html
  44. 44.Paparini S, Whelan I, Mwendera C, et al. Prevention of sexual transmission of mpox: a systematic review and qualitative evidence synthesis of approaches. Infect Dis (Lond). 2024;56(8):589-605.
  45. 45.Jongen VW, Groot Bruinderink ML, Boyd A, et al. What determines mpox vaccination uptake? Assessing the effect of intent-to-vaccinate versus other determinants among men who have sex with men. Vaccine. 2024;42(2):186-193.
  46. 46.Centers for Disease Control and Prevention. How mpox spreads. https://www.cdc.gov/mpox/causes/index.html
  47. 47.Centers for Disease Control and Prevention. Signs and symptoms of mpox. https://www.cdc.gov/mpox/signs-symptoms/index.html
  48. 48.Centers for Disease Control and Prevention. Mpox vaccination. https://www.cdc.gov/mpox/vaccines/index.html
  49. 49.Sulaiman SK, Isma’il Tsiga-Ahmed F, Musa MS, et al. Global prevalence and correlates of mpox vaccine acceptance and uptake: a systematic review and meta-analysis. Commun Med (Lond). 2024;4(1):136.
  50. 50.Zheng M, Du M, Yang G, et al. Mpox vaccination hesitancy and its associated factors among men who have sex with men in China: a national observational study. Vaccines (Basel). 2023;11(9):1432.
  51. 51.Dalton AF, Diallo AO, Chard AN, et al.; CDC Multijurisdictional Mpox Case-Control Study Group, CDC Multijurisdictional Mpox Case Control Study Group. Estimated effectiveness of JYNNEOS vaccine in preventing mpox: a multijurisdictional case-control study – United States, August 19, 2022-March 31, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(20):553-558.
  52. 52.Chesson HW, Dunne EF, Hariri S, et al. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660-664.
  53. 53.Lewis RM, Laprise JF, Gargano JW, et al. Estimated prevalence and incidence of disease-associated human papillomavirus types among 15- to 59-year-olds in the United States. Sex Transm Dis. 2021;48(4):273-277.
  54. 54.Rosenblum HG, Lewis RM, Gargano JW, et al. Declines in prevalence of human papillomavirus vaccine-type infection among females after introduction of vaccine - United States, 2003-2018. MMWR Morb Mortal Wkly Rep. 2021;70(12):415-420.
  55. 55.Mangione CM, Barry MJ, Nicholson WK, et al.; US Preventive Services Task Force. Serologic screening for genital herpes infection: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2023;329(6):502-507.
  56. 56.Centers for Disease Control and Prevention. 2022 viral hepatitis surveillance report. https://www.cdc.gov/hepatitis-surveillance-2022/about/index.html
  57. 57.Centers for Disease Control and Prevention. Hepatitis B surveillance. https://www.cdc.gov/hepatitis-surveillance-2022/hepatitis-b/
  58. 58.Kim WR. Epidemiology of hepatitis B in the United States. Hepatology. 2009;49(5 suppl):S28-S34.
  59. 59.Centers for Disease Control and Prevention. Hepatitis C surveillance. https://www.cdc.gov/hepatitis-surveillance-2022/hepatitis-c/
  60. 60.Centers for Disease Control and Prevention. HIV surveillance supplemental report: estimated HIV incidence and prevalence in the United States, 2018-2022. https://stacks.cdc.gov/view/cdc/156513
  61. 61.Centers for Disease Control and Prevention. Fast facts: HIV in the United States. https://www.cdc.gov/hiv/data-research/facts-stats/index.html

Current edition

Hepatitis Overview

Hepatitis Overview

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.